Recent research has elucidated the significance of the CD2/CD58 as a main co‐stimulatory pathway in human CD28−CD8+ T cells[59] This discovery implies that SEB variants, which enhance co‐stimulatory signals through CD2 and CD58 interactions, may hold the potential to rejuvenate T cell responses, thereby offering new opportunities for cancer immunotherapy strategies. This evidence concerns the gene CD58 and cancer.